Key Highlights

  • On July 6 2026, InMed Pharmaceuticals Inc. And Mentari Therapeutics executed Amendment No. 1 to their merger agreement.
  • The amendment requires InMed to adopt the name Mentari Therapeutics before the merger closing date.
  • Redomestication to Nevada is slated for the closing date, supporting a Section 368(a) tax reorganization.
  • A Form S‑4 registration statement was filed on July 2 2026, containing a joint proxy and prospectus.

InMed Pharmaceuticals Inc. (NASDAQ: INM) announced a formal amendment to its pending merger with Mentari Therapeutics, Inc. The amendment clarifies transaction sequencing, introduces a new financing mechanism, and confirms the tax treatment of the combined entity.

Amendment Overview

The July 6 2026 amendment revises the original May 19 2026 merger agreement between InMed Pharmaceuticals, its two merger subsidiaries, and Mentari Therapeutics. The revised terms preserve all existing provisions except for the specific updates outlined in the amendment.

Name Change and Redomestication

InMed Pharmaceuticals will rename itself Mentari Therapeutics ahead of the merger’s closing.

PIPE Financing Provision

The amendment adds a “Company PIPE Amendment” that permits InMed to raise additional private‑placement funds before the merger finalizes. Any such financing will be reflected in the exchange ratio that determines share conversions for existing shareholders.

Tax Reorganization Confirmation

By removing the prior contingency for a Cayman Islands redomestication, the amendment confirms that the combined mergers will qualify as a single integrated reorganization under the tax code. This clarification aims to secure favorable tax outcomes for the merged entity.

Regulatory Filings and Proxy

A registration statement on Form S‑4 was filed on July 2 2026, providing a preliminary joint proxy statement and prospectus for the proposed transaction. The filing details the intended Nasdaq listing of the combined company following the merger’s completion.

Forward‑Looking Statements and Risks

The amendment contains forward‑looking statements regarding timing, shareholder approvals, and regulatory clearances. Risks cited include possible delays in financing, failure to obtain required approvals, and potential impacts on Nasdaq listing status.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.